AAN | Acumen Pharmaceuticals

AAN Presentation

April 7, 2025/in 2025 AAN, ALTITUDE-AD, Presentation, pTau217, sabirnetug, TwentyTwentyFive /by Robyn Moxon

2025 AAN Presentation:

ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease

2024 AAN Presentation

May 31, 2024/in 2024 2024, AAN, Biomarkers, INTERCEPT-AD, Presentation, Target Engagement, TwentyTwentyFour /by Robyn Moxon

2024 AAN Presentation:

A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.

2024 AAN Poster

May 31, 2024/in 2024 2024, AAN, Biomarkers, INTERCEPT-AD, Poster, Target Engagement, TwentyTwentyFour /by Robyn Moxon

2024 AAN Poster:

A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.